Invesco Biotechnology & Genome ETF
PBE
96 hedge funds and large institutions have $88M invested in Invesco Biotechnology & Genome ETF in 2024 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 20 increasing their positions, 31 reducing their positions, and 9 closing their positions.
1.03% more ownership
Funds ownership: 34.63% → 35.66% (+1%)
5% less capital invested
Capital invested by funds: $92.4M → $88M (-$4.39M)
6% less funds holding
Funds holding: 102 → 96 (-6)
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
35% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$2.05M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$590K |
| 3 |
GKWIM
Gerber Kawasaki Wealth & Investment Management
Santa Monica,
California
|
+$450K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$307K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$259K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CW
CreativeOne Wealth
Overland Park,
Kansas
|
-$353K |
| 2 |
Pathstone Holdings
Englewood,
New Jersey
|
-$345K |
| 3 |
Jane Street
New York
|
-$295K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$261K |
| 5 |
WBG
Wharton Business Group
Malvern,
Pennsylvania
|
-$252K |
PBE Hedge Fund Activity: Q4 2024 in Review
96 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q4 2024, worth a combined $88M — down 4.7% from $92.4M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of PBE and 8 opened new positions — a net loss of 1 holder — while 31 trimmed existing stakes and 20 added.
The largest buyer was Goldman Sachs, adding an estimated $2.05M. The largest seller was CreativeOne Wealth, cutting an estimated $353K.
- 96 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q4 2024, down from 102 in Q3 2024.
- Funds reported $88M of Invesco Biotechnology & Genome ETF stock for Q4 2024, down 4.7% quarter-over-quarter.
- 8 funds opened new Invesco Biotechnology & Genome ETF positions in Q4 2024 and 9 closed out, a net change of -1 holder.
- The largest Invesco Biotechnology & Genome ETF buyer in Q4 2024 was Goldman Sachs, an estimated $2.05M added.
- The largest Invesco Biotechnology & Genome ETF seller in Q4 2024 was CreativeOne Wealth, an estimated $353K sold.
Based on aggregated 13F filings for Q4 2024.